Related Experiment Video
Updated: Aug 10, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
The Potential Influence of Advanced Glycation End Products and (s)RAGE in Rheumatic Diseases
Charlotte Delrue1, Reinhart Speeckaert2, Joris R Delanghe3
1Department of Nephrology, Ghent University Hospital, 9000 Ghent, Belgium.
Abstract:
Advanced glycation end products (AGEs) are a class of compounds formed by nonenzymatic interactions between reducing sugars and proteins, lipids, or nucleic acids. AGEs can alter the protein structure and activate one of their receptors, specifically the receptor for advanced glycation end products (RAGE). These phenomena impair the functions of cells, extracellular matrix, and tissues. RAGE is expressed by a variety of cells and has been linked to chronic inflammatory autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, and Sjögren's syndrome. The soluble (s)RAGE cleavage product is a positively charged 48-kDa cleavage product that retains the ligand binding site but loses the transmembrane and signaling domains. By acting as a decoy, this soluble receptor inhibits the pro-inflammatory processes mediated by RAGE and its ligands. In the present review, we will give an overview of the role of AGEs, sRAGE, and RAGE polymorphisms in several rheumatic diseases. AGE overproduction may play a role in the pathogenesis and is linked to accelerated atherosclerosis. Low serum sRAGE concentrations are linked to an increased cardiovascular risk profile and a poor prognosis. Some RAGE polymorphisms may be associated with increased disease susceptibility. Finally, sRAGE levels can be used to track disease progression.
Insights
Advanced glycation end products (AGEs) impact cell function and are linked to rheumatic diseases. Soluble RAGE (sRAGE) acts as a decoy, and its levels may indicate disease progression and cardiovascular risk.
Area of Science:
- Biochemistry
- Immunology
- Rheumatology
Background:
- Advanced glycation end products (AGEs) form from sugar-protein interactions, altering protein structure and activating the receptor for advanced glycation end products (RAGE).
- RAGE activation contributes to cellular and tissue dysfunction, and is implicated in chronic inflammatory autoimmune disorders like rheumatoid arthritis, lupus, and Sjögren's syndrome.
- The soluble form of RAGE (sRAGE) acts as a decoy receptor, inhibiting RAGE-mediated pro-inflammatory signaling.
Purpose of the Study:
- To review the roles of AGEs, sRAGE, and RAGE polymorphisms in rheumatic diseases.
- To explore the connection between AGE overproduction, atherosclerosis, and disease pathogenesis.
- To examine the clinical significance of sRAGE levels and RAGE polymorphisms in rheumatic conditions.
Main Methods:
- Literature review of studies investigating AGEs, RAGE, and sRAGE in rheumatic diseases.
- Analysis of the biochemical mechanisms of AGEs and RAGE signaling.
- Examination of the association between RAGE polymorphisms and disease susceptibility.
Main Results:
- AGE overproduction is linked to rheumatic disease pathogenesis and accelerated atherosclerosis.
- Low serum sRAGE concentrations correlate with increased cardiovascular risk and poorer prognosis.
- Certain RAGE polymorphisms may be associated with heightened susceptibility to rheumatic diseases.
Conclusions:
- AGEs and RAGE play significant roles in the development and progression of rheumatic diseases.
- sRAGE levels serve as a potential biomarker for disease activity, cardiovascular risk, and prognosis.
- RAGE polymorphisms represent a potential genetic factor influencing disease susceptibility in rheumatic conditions.
More Related Videos
06:05Advanced Glycation End-Products Sensitize Human Sensory-Like Neuron Cells to Capsaicin-Induced Calcium Influx
Published on: May 2, 2025
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Proteoglycans
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The JAK-STAT Signaling Pathway
Rheumatic Heart Disease III: Medical Management